RxDoctor Payments Data

Crystal Haus

Family · Natrona Heights, PANPI 1205233194

Payments from drug & device makers

$2,946in general payments, 2019–2025

Across 118 payments — averaging $24.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$349
  • Johnson & Johnson$310
  • Scpharmaceuticals Inc.$306
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$290
  • Amgen$268
  • Edwards Lifesciences$226
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,946100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,946 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,123
Medicare patients
35
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$158,409
XareltoRivaroxaban67$62,462
EntrestoSacubitril/Valsartan61$59,296
JardianceEmpagliflozin45$48,153
Repatha SureclickEvolocumab49$37,111
BrilintaTicagrelor13$7,561
Metoprolol Succinate315$3,241
Valsartan80$2,664
Rosuvastatin Calcium148$2,296
Diltiazem 24hr Er (Cd)Diltiazem Hcl55$1,540
Ranolazine ErRanolazine23$1,288
Atorvastatin Calcium124$1,179
Isosorbide Mononitrate ErIsosorbide Mononitrate109$1,154
Ezetimibe44$788
ClopidogrelClopidogrel Bisulfate78$689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$349$158,409177 claims
Johnson & JohnsonXarelto$310$62,46267 claims
NovartisEntresto$33$59,29661 claims
AstraZenecaBrilinta$192$7,56113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.

Other family in Natrona Heights

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →